{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+IV+administration+of+vancomycin",
    "query": {
      "intervention": "Standard IV administration of vancomycin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 23,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+IV+administration+of+vancomycin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T07:44:11.994Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00061633",
      "title": "Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infections, Gram-Positive Bacterial",
        "Abscess",
        "Burns",
        "Cellulitis",
        "Ulcer",
        "Wound Infections"
      ],
      "interventions": [
        {
          "name": "Telavancin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin or antistaphylococcal penicillin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cumberland Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2003-06",
      "completion_date": "2004-01",
      "has_results": true,
      "last_update_posted_date": "2019-01-16",
      "last_synced_at": "2026-09-10T07:44:11.994Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00061633"
    },
    {
      "nct_id": "NCT03137173",
      "title": "Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Bacterial Skin and Skin Structure Infections"
      ],
      "interventions": [
        {
          "name": "ceftobiprole medocaril",
          "type": "DRUG"
        },
        {
          "name": "vancomycin+aztreonam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 679,
      "start_date": "2018-02-19",
      "completion_date": "2019-04-22",
      "has_results": true,
      "last_update_posted_date": "2023-05-12",
      "last_synced_at": "2026-09-10T07:44:11.994Z",
      "location_count": 16,
      "location_summary": "Anaheim, California • Chula Vista, California • Fresno, California + 10 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03137173"
    },
    {
      "nct_id": "NCT05705843",
      "title": "IO vs IV Vancomycin in Tourniquetless TKA",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infection, Surgical Site"
      ],
      "interventions": [
        {
          "name": "Intraosseous Vancomycin Injection",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "19 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2023-01-25",
      "completion_date": "2024-01-25",
      "has_results": false,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-09-10T07:44:11.994Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05705843"
    },
    {
      "nct_id": "NCT00711802",
      "title": "Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Skin Diseases, Infectious"
      ],
      "interventions": [
        {
          "name": "Daptomycin",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 396,
      "start_date": "2008-07-23",
      "completion_date": "2013-10-11",
      "has_results": true,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-09-10T07:44:11.994Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Oakland, California • Orange, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00711802"
    },
    {
      "nct_id": "NCT04317963",
      "title": "Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Clostridium Difficile Infection",
        "Clostridium Difficile Infection Recurrence"
      ],
      "interventions": [
        {
          "name": "Bezlotoxumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard CDI treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Illinois at Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2020-02-12",
      "completion_date": "2023-02-22",
      "has_results": false,
      "last_update_posted_date": "2023-02-28",
      "last_synced_at": "2026-09-10T07:44:11.994Z",
      "location_count": 1,
      "location_summary": "Maywood, Illinois",
      "locations": [
        {
          "city": "Maywood",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04317963"
    },
    {
      "nct_id": "NCT04911270",
      "title": "Clinical Decision Support Tool for Vancomycin Dosing in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Gram-Positive Bacterial Infections",
        "Vancomycin",
        "Pharmacokinetics",
        "Pharmacodynamics"
      ],
      "interventions": [
        {
          "name": "Computer Decision Support Tool Intervention Group",
          "type": "DEVICE"
        },
        {
          "name": "Matched Historical Controls",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 75,
      "start_date": "2022-05-09",
      "completion_date": "2025-05-10",
      "has_results": false,
      "last_update_posted_date": "2025-05-14",
      "last_synced_at": "2026-09-10T07:44:11.994Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04911270"
    },
    {
      "nct_id": "NCT06384651",
      "title": "Intraosseous vs. Intravenous Vancomycin Administration in Total Ankle Arthroplasty",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infections",
        "Ankle Arthritis"
      ],
      "interventions": [
        {
          "name": "Intraosseous Vancomycin Injection",
          "type": "DRUG"
        },
        {
          "name": "Intravenous Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2024-12-03",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-01-24",
      "last_synced_at": "2026-09-10T07:44:11.994Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06384651"
    },
    {
      "nct_id": "NCT04678154",
      "title": "Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Post Operative Surgical Site Infection"
      ],
      "interventions": [
        {
          "name": "Standard of care",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin and Tobramycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Major Extremity Trauma Research Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 600,
      "start_date": "2021-05-07",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-09-10T07:44:11.994Z",
      "location_count": 31,
      "location_summary": "Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more",
      "locations": [
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04678154"
    },
    {
      "nct_id": "NCT04775953",
      "title": "DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Staphylococcal Bacteraemia"
      ],
      "interventions": [
        {
          "name": "Cefazolin",
          "type": "DRUG"
        },
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Daptomycin",
          "type": "DRUG"
        },
        {
          "name": "Nafcillin",
          "type": "DRUG"
        },
        {
          "name": "Oxacillin",
          "type": "DRUG"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 200,
      "start_date": "2021-04-22",
      "completion_date": "2023-12-01",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-09-10T07:44:11.994Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04775953"
    },
    {
      "nct_id": "NCT04729322",
      "title": "Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Colorectal Adenocarcinoma",
        "Metastatic Small Intestinal Adenocarcinoma",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Small Intestinal Adenocarcinoma AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Fecal Microbiota Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Fecal Microbiota Transplantation Capsule",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole",
          "type": "DRUG"
        },
        {
          "name": "Neomycin",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-02-22",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-09-10T07:44:11.994Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04729322"
    }
  ]
}